4.2 Article

Bone and mineral disorders after kidney transplantation: Therapeutic strategies

期刊

TRANSPLANTATION REVIEWS
卷 28, 期 2, 页码 56-62

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.trre.2013.12.003

关键词

-

资金

  1. Abbott
  2. Amgen
  3. DaVita
  4. Fresenius-Kabi
  5. Genzyme
  6. Otsuka
  7. Shire

向作者/读者索取更多资源

Mineral and bone diseases (MBD) are common in patients with chronic kidney disease who undergo kidney transplantation. The incidence, types and severity of MBD vary according to the duration of chronic kidney disease, presence of comorbid conditions and intake of certain medications. Moreover, multiple types of pathology may be responsible for MBD. After successful reversal of uremia by kidney transplantation, many bone and mineral disorders improve, while immunosuppression, other medications, and new and existing comorbidities may result in new or worsening MBD. Chronic kidney disease is also common after kidney transplantation and may impact bone and mineral disease. In this article, we reviewed the prevalence, pathophysiology, and impact of MBD on post-transplant outcomes. We also discussed the diagnostic approach; immunosuppression management and potential treatment of MBD in kidney transplant recipients. (C) 2014 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据